The most common grade @-@ adverse events were diarrhoea ( @ -LSB- @ % -RSB- patients on dacomitinib vs no controls ) , acneiform rash ( @ -LSB- @ % -RSB- vs one -LSB- < @ % -RSB- ) , oral mucositis ( @ -LSB- @ % -RSB- vs none ) , and fatigue ( @ -LSB- @ % -RSB- vs four -LSB- @ % -RSB- ) .